Construction of a novel six-gene signature to predict tumour response to induction chemotherapy and overall survival in locoregionally advanced laryngeal and hypopharyngeal carcinoma  

作　　者：Chen Tan Lingwa Wang Yifan Yang Shizhi He George G.Chen Jason YK.Chan Michael CF.Tong C.A.van Hasselt Wenbin Xu Ling Feng Ru Wang Jugao Fang 

机构地区：[1]Department of Otolaryngology Head and Neck Surgery,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China [2]Key Laboratory of Otolaryngology Head and Neck Surgery(Ministry of Education of China),Beijing Institute of Otolaryngology,Beijing 100730,China [3]Department of Otorhinolaryngology,Head and Neck Surgery,The Chinese University of Hong Kong,Prince of Wales Hospital,HongKong SAR999077,China [4]Department of Medical Genetics,Institute of Basic Medical Science,Chinese Academy of Medical Science&Peking Union Medical Collage,Beijing 100730,China

出　　处：《Genes & Diseases》2024年第3期148-150,共3页基因与疾病（英文）

基　　金：supported by the National Key R&D Program of China(No.2020YFB1312805).

摘　　要：Locoregionally advanced laryngeal and hypopharyngeal cancers(LA-LHCs)are traditionally treated with surgery followed by postoperative radiotherapy,which impairs speech and swallowing functions and reduces the quality of life.^(1,2)The use of induction chemotherapy(IC)as a larynxpreserving approach for LA-LHCs has been verified and refined.^(3)However,the short-term tumor response to IC varies,non-responders usually show poor survival and little benefit.

关 键 词：CHEMOTHERAPY LARYNGEAL SURGERY 

分 类 号：R739.6[医药卫生—肿瘤]